Iodide transport defect is a disorder characterized by an inability of the thyroid to maintain an iodide concentration difference between the plasma and the thyroid. The recent cloning of the sodium/iodide symporter (NIS) gene enabled us to characterize the NIS gene in this disorder. We identified a homozygous missense mutation of A3 C at nucleotide ϩ1060 in NIS complementary DNA in a male patient who was born from consanguineous marriage, had a huge goiter, and lacked the ability to accumulate iodide but was essentially euthyroid.
I
ODIDE TRANSPORT defect (OMIM 274400) is a rare disorder characterized by an inability of the thyroid to maintain a concentration difference of readily exchangeable iodide between the plasma and the thyroid. The defect is also found in the salivary glands and gastric mucosa, and is presumed to arise either because of a defective supply of energy for the transport system or because of abnormality of a carrier or receptor substance for iodide (1, 2) .
To date, 37 cases from 22 families with this disorder have been reported (1) (2) (3) (4) (5) (6) (7) (8) . Diagnosis is made by 1) absence or poor radioactive iodide uptake without iodide overload, 2) defective iodide condensation in salivary and gastric glands, 3) apparent or latent hypothyroidism that becomes evident when iodide intake is restricted and can be restored by iodide administration, and 4) exclusion of other defects in the process of thyroid hormone synthesis. The entity of this disorder is clearly defined, and no diagnostic errors are possible, as Leger et al. pointed out (5) .
Recent studies revealed that iodide is totally cotransported with sodium by the Na ϩ /I Ϫ symporter (NIS) in the plasma membrane of the thyroid cells (9, 10) . NIS plays an initial and rate-limiting step in synthesis of iodide-containing thyroid hormones. NIS concentrates iodide in thyroid cells by active transport countering an electrochemical gradient and maintains iodide concentrations in thyroid cells about 20-to 100-fold those in serum. In 1996, rat (11) and human (12) NIS complementary DNA (cDNA) sequences were reported. The deduced amino acid sequence revealed that NIS is an intrinsic membrane protein with 12 putative transmembrane domains and is a member of Na ϩ /solute cotransporter family. These advances have focused on the NIS gene as a candidate disease gene for iodide transport defect.
Here, we report a loss-of-function mutation of the NIS gene in a patient with iodide transport defect and discuss the pathophysiology and mechanism of compensation by intake of large amounts of iodide.
Subjects and Methods

Case reported 23 yr ago
A male Japanese patient with iodide transport defect was presented in a local report 23 yr ago (3) and was reviewed in Ref. 2 as case 11. He had had no health problems before diffuse goiter was noted at 18 yr of age. At the age of 30 yr, he consulted a hospital complaining of a huge goiter and easy fatiguability, but was diagnosed to be euthyroid. Examination 5 yr later (3) revealed that he had a huge diffuse goiter and was euthyroid, but thyroidal 131 I uptake was continuously very low for 72 h after administration; 4% at 3 h and 3% at 24 h.
131 I uptake did not increase after administration of 10 U TSH over the successive 3 days. Most of the administered 131 I was rapidly excreted in urine. Saliva/ serum and gastric juice/serum 131 I ratios at 4 h were 1. 
Present examinations
We reevaluated the patient, who is now 60 yr old. He had no developmental or intellectual problems, was 173 cm in height, and had a body weight of 73 kg. He had a diffuse, elastic-soft, and smooth-surfaced goiter with a transverse diameter of 11.5 cm as detected by ultrasonography. He was clinically euthyroid and lacked eye symptoms and other abnormal findings on physical examination. Laboratory data confirmed that he was euthyroid. No abnormal findings were found in chemical or hematological examinations. Essentially no thyroidal 123 I uptake was observed (1.4% at 3 h and 2.5% at 24 h after administration; normal range, 7-35%). Salivary glands showed no accumulation of iodide either. Iodide concentrations in urine and serum were 610 and 64 g/L, respectively, which are in the high normal ranges for Japanese subjects (13, 14) , indicating no overload but relatively high intake of iodide compared with world standard (15) . Antibodies against thyroglobulin, thyroid peroxidase, and TSH receptor were negative. We performed open biopsy of the thyroid to examine NIS cDNA with the patient's informed consent.
Ribonucleic acid (RNA) isolation, reverse transcription-PCR (RT-PCR), and direct sequencing
Total RNA was extracted by the acid guanidinium/phenol/chloroform method from approximately 100 mg thyroid tissue using RNAzol B (Biotecx Laboratories, Houston, TX) from the patient's and normal thyroid tissues. The normal control thyroid was the tissue surrounding a benign thyroid adenoma removed surgically. RT was performed on 2 g total RNA (preheated at 70 C for 10 min) in 40 L reaction buffer [25 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 2 mmol/L dithiothreitol, and 5 mmol/L MgCl 2 ] containing 30 pmol oligo(deoxythymidine) 15 primer, 20 U avian myeloblastosis virus reverse transcriptase XL (Life Sciences, Petersburg, FL), and 40 U ribonuclease inhibitor (Toyobo, Osaka, Japan) at 42 C for 40 min. For PCR amplification of NIS cDNA (nucleotides Ϫ59 to ϩ1975 containing the full-length coding region), 4 L RT reaction solution were incorporated in 100 L PCR buffer [60 mmol/L Tris-HCl (pH 8.5), 15 mmol/L (NH 4 ) 2 SO 4 , 1.5 mmol/L MgCl 2 , and 10% dimethylsulfoxide] containing 2 U Taq polymerase (Takara, Tokyo, Japan), 2 U Taq Extender PCR additive (Stratagene, La Jolla, CA), and 50 pmol each of oligonucleotide primers (5Ј-TTCCCCCGCTTGAG-CACGCAGG-3Ј and 5Ј-GAGGTTCCATCCCAGGGTGTCAG-3Ј). Samples were denatured for 5 min at 94 C and then subjected to 30 cycles consisting of 1 min at 94 C, 1 min at 58 C, and 2 min at 72 C. The last extension was carried out for 12 min. Direct full-length sequencing of the purified PCR product was performed using Exo(Ϫ)Pfu DNA polymerase (Stratagene) and primers specific to the reported human NIS cDNA sequence (12) .
Analysis of genomic DNA
Genomic DNA from the patient, his family members, and normal subjects was extracted from peripheral blood cells using a WB kit (Wako, Tokyo, Japan). A portion of NIS DNA surrounding the identified mutation was amplified by PCR with primers 5Ј-AAGATCTGCCTG-GAGTCC-3Ј (corresponding to nucleotides ϩ1001 to ϩ1018) and 5Ј-CAGTGACTGCAGCCATAG-3Ј (corresponding to nucleotides ϩ1099 to ϩ1082). The purified product that was approximately 1.1 kilobase (kb) in length was subjected to direct sequencing using the same primers.
Construction of expression vectors, transfection, and iodide uptake assay
PCR-amplified mutant and wild-type human NIS cDNAs were directly inserted by TA cloning into the pCR3.1 vector under control of cytomegalovirus promoter (Invitrogen, Carlsbad, CA). The full-length nucleotide sequences of the constructs were confirmed. COS-7 cells were transfected with 25 g mutant or wild-type NIS DNA or control vector DNA (pCR3-CAT, Invitrogen) by electroporation (Bio-Rad, Richmond, CA). Transfection efficiencies were monitored by cotransfection with pSVGH and measurement of GH concentration in culture medium. Cells were aliquoted into 24-well plates (ϳ10 5 cells/well). Forty-eight hours after transfection, assays of iodide uptake were performed as previously described (16, 17) . Briefly, cells were incubated with 125 I and 10 mol/L NaI in HBSS containing 0.5% (wt/vol) BSA and HEPES (2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid)-NaOH at pH 7.4 for 2-5 min at 37 C. After incubation, cells were quickly washed twice with ice-cold incubation solution without iodide, and subjected to radioactivity measurement. The assays were repeated three times. The total cell protein concentration was measured with the Bio-Rad protein assay system.
Northern analysis
Ten micrograms of total RNA were electrophoresed in 1% agarose gels containing 0.66 mol/L formaldehyde and blotted onto nylon filters (Hybond N ϩ , Amersham, Aylesbury, UK) according to the manufacturer's instructions. As a mol wt marker, a 0.24-to 9.5-kb RNA ladder (Life Technologies Gaithersburg, MD) was used. Purified full-length NIS cDNA probe (Ϫ59 to ϩ1975) and human ␤-actin cDNA probe (Nippon Gene, Tokyo, Japan) were radiolabeled by random priming. Hybridization (0.5-1.0 ϫ 10 6 cpm/mL) and washing were performed as previously described (18) ; final washings were carried out at 65 C in 1 ϫ SSPE (150 mmol/L NaCl, 10 mmol/L NaH 2 PO 4 , and 1 mmol/L ethylenediaminetetraacetic acid, pH 7.4)-0.1% SDS. 
Results
The diagnosis was confirmed by lack of 1) radioactive iodide uptake without iodide overload; 2) condensation of iodide in the thyroid, salivary glands, and stomach; and 3) abnormalities in iodide organification, peroxidase activity, or thyroglobulin. The patient had had a huge diffuse goiter since 18 yr of age. He was euthyroid while consuming normal meals (relatively high iodide content), hypothyroid with iodide-poor meals for 3 weeks, and became euthyroid when administered large amounts of iodide (Table 1) . It was not noted in the original report (3), but our further interview revealed that his parents were second degree relatives (cousins; Fig. 1) . Histologically, the thyroid specimen showed diffuse hyperplasia of thyrocytes. All of the above observations satisfy the criteria for diagnosis of the iodide transport defect reported by Stanbury et al. (19) . To investigate whether the NIS gene is involved in the iodide transport defect, we examined the NIS gene in this patient.
We performed RT-PCR using total RNA from the thyroid obtained by open biopsy. The NIS RT-PCR product was subjected to direct sequencing. A homozygous nucleotide substitution of A to C was present at nucleotide position ϩ1060, which changed Thr 354 to Pro (ACA3CCA) in the middle of the ninth transmembrane domain (Fig. 2) . No other nucleotide changes from the reported sequence (12) were found in the region from nucleotides Ϫ37 to ϩ1952 containing the full coding region. These observations were also confirmed by completely sequencing 12 independent clones obtained by direct TA cloning of the PCR product in pCR3.1 vector (Invitrogen).
PCR amplification of genomic DNA from peripheral blood cells of the patient, his daughter, his wife, and 13 normal subjects with primers to amplify a region from nucleotides ϩ1001 to ϩ1099 of NIS cDNA yielded a ϳ1.1-kb fragment. Direct sequencing of the PCR product using the same primers revealed an intron of ϳ1.0 kb between nucleotides ϩ1058 and ϩ1059 of the NIS cDNA (Fig. 3) . The patient had the same homozygous mutation as that found in cDNA in the thyroid (Fig. 4) . His daughter was heterozygous for the mutation; she was euthyroid (Table 2) and had no goiter, supporting the recessive nature of the disease. His wife and 13 normal subjects had no base substitution in this region (Fig. 4) .
FIG. 2.
Direct sequence of NIS cDNA of the patient. Antisense sequences of NIS cDNA from the patient and normal thyroid are shown. G and C, and A and T are conversely labeled, respectively, for easy reading. Sequences were confirmed in both orientations and in full length (nucleotides Ϫ37 to ϩ1952). The patient had a homozygous A to C substitution at nucleotide ϩ1060, which changed Thr 354 to Pro in the ninth putative transmembrane domain. No other nucleotide changes from the reported sequence (12) were found in the region from nucleotide Ϫ37 to ϩ1952 containing the full coding region. Homozygosity was also confirmed by cloning the PCR product and sequencing. All 12 independent clones sequenced had the same mutation.
FIG. 3.
Genomic DNA sequence of a portion of NIS gene. Genomic DNA was amplified using primers 5Ј-AAGATCTGCCTGGAGTCC-3Ј (corresponding to nucleotides ϩ1001 to ϩ1018) and 5Ј-CAGTGACT-GCAGCCATAG-3Ј (corresponding to nucleotides ϩ1099 to ϩ1082) and was directly sequenced with the same primers. The intronic sequence is shown in lowercase letters, and the exonic sequence is shown in uppercase letters. Exon/intron boundaries and deduced amino acid sequences from the cDNA report (12) are shown. Otherwise, only sequence information from this sequence reaction is shown. Consensus sequences of exon/intron boundary (underlined) are aligned. M, (A/C); r, (a/g); y, (c/t); n, (g/a/t/c). Bases conforming to this consensus are shown in boldface. This intronic sequence appeared in good accordance with that reported by Smanik et al. (25) , published while this paper was in review, but not with that reported by Fujiwara et al. (23) .
Expression vectors were constructed for the mutant (T354P) and wild-type NIS genes and transfected into COS-7 cells simultaneously. Cells with the mutant NIS gene showed very low level (ϳ0.4% of that in cells with wild-type NIS), but still significant, perchlorate-sensitive iodide uptake compared with that in cells transfected with control vector (pCR3-CAT, Invitrogen; Fig. 5 ). Cotransfection with pSVGH and measurement of GH concentrations in the media showed no differences in transfection efficiencies.
Northern analysis showed that the NIS/␤-actin messenger RNA (mRNA) ratio of the patient's thyroid was more than 100-fold higher than that of normal thyroid obtained from tissue adjacent to benign thyroid adenoma (Fig. 6) . TSH levels at open biopsy and operation were 6.2 and 3.2 mU/L, respectively. The size of NIS mRNA in the thyroid was ϳ2.9 kb, similar to that of rat NIS mRNA in FRTL5 rat thyroid cells (20) , and this was not different between the patient and the normal subject (Fig. 6) .
Discussion
We identified a homozygous missense mutation (Thr 354 3 Pro; ACA3 CCA) of the NIS cDNA in a patient with iodide transport defect who was born from a consanguineous marriage. This mutation itself was confirmed to be the direct cause of the disease in this patient by expression experiments that showed markedly decreased iodide uptake in cells expressing the mutant and by Northern analysis that showed an increase, not a decrease, in NIS mRNA level in the patient's thyroid compared with that in normal thyroid. The amino acid sequence of the ninth transmembrane domain of NIS, in the middle of which the mutation exists, is entirely conserved in rat and human homologs, suggesting a conservative structural and/or functional significance of this domain of NIS. However, we must await detailed threedimensional characterization by mutagenesis, modeling, and purification before discussing the role of this portion and the kinking effect by proline introduction.
Although the entity of iodide transport defect appears clearly defined as described above, the clinical features of this disorder seem heterogeneous. Some patients show cretinism, and some remain euthyroid without mental or developmental disorders, as in this case (2) . Most have goiter, but some cases without goiter have been reported (2) . The amount of iodide intake has been suggested to influence the differences in the clinical picture (2) . Investigation of the NIS gene in other patients with this disorder might facilitate elucidation of the genotype-phenotype relationship.
The compensation mechanism for poor or lack of iodide accumulation by NIS remains unclear. However, iodide administration was reported to cure hypothyroidism and reduce goiter size (2), as in this case. Transport of iodide through nonspecific channels or carriers might compensate for low uptake if relatively large amounts of iodide are taken (2) . Alternatively, in this case very low NIS activity might have been compensated for by overexpression of the gene, although whether the mutant NIS protein is actually overexpressed in the plasma membrane has not been clarified.
Very recently, Kogai et al. (20) reported that TSH increased the level of NIS mRNA in FRTL-5 cultured rat thyroid cells. This increase in message was maximum (up to 8-fold from the basal level without TSH stimulation) at 1 U/L TSH. At the time of open biopsy in our case, the TSH level was slightly increased. However, it cannot account for the marked (Ͼ100-fold) increase in the NIS message in the case with iodide transport defect. Our present observations may provide insight into another important mechanism of transcriptional regulation of NIS, such as by iodide itself or forms of organic iodine, as suggested by a mechanism called autoregulation by iodine (21, 22) . Further, variability in the clinical picture among cases with iodide transport defect might be explained by the difference in NIS gene expression as well as differences in genotype. It is interesting that Inomata et al. (8) reported siblings born from a consanguineous marriage with different clinical pictures of iodide transport defect. Investigation of NIS gene expression will promote understanding of the pathophysiology not only of the iodide transport defect but also of the iodide deficiency from which tens of millions of people in the world suffer.
The iodide transport defect is usually evident in salivary and gastric glands as well as in the thyroid. Identification of a loss-of-function mutation of the NIS gene in a patient showing no condensation of radioactive iodide in saliva or gastric juice supports the existence of NIS in these tissues, although it has not been proven directly, and the physiological significance of NIS in these tissues is not yet clear.
During the preparation of this manuscript, the identical NIS mutation was reported by Fujiwara et al. in Osaka in a patient with congenital hypothyroidism (23) . Our patient has origins from Wakayama prefecture adjacent to Osaka prefecture. Although there was no known familial relationship between these two cases, descendency from a common ancestor origin should be considered. Alternatively, this mutation might be in a hot spot. It is interesting to compare the clinical features between the cases, although these were not documented in detail in their report (23) . In their report, cells expressing the T354P mutant showed iodide uptake indistinguishable from that by control cells (23) . The discrepancy from the results of our expression study might have been due to low and/or noncontrolled transfection efficiency or lack of comparisons with iodide uptake in the presence of perchlorate. Electrophysiological examinations in the presence of high concentrations of iodide might resolve this discrepancy (24) .
